LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $110.60.

Several analysts have weighed in on the stock. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wells Fargo & Company decreased their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 14th. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Tidal Investments LLC purchased a new position in shares of LeMaitre Vascular in the second quarter valued at about $526,000. Engineers Gate Manager LP raised its stake in LeMaitre Vascular by 38.4% in the second quarter. Engineers Gate Manager LP now owns 14,008 shares of the medical instruments supplier’s stock worth $1,344,000 after buying an additional 3,888 shares in the last quarter. Nykredit A S purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $82,000. Corient Private Wealth LP lifted its stake in shares of LeMaitre Vascular by 62.8% in the 2nd quarter. Corient Private Wealth LP now owns 25,589 shares of the medical instruments supplier’s stock valued at $2,456,000 after purchasing an additional 9,875 shares during the period. Finally, Grandeur Peak Global Advisors LLC grew its stake in LeMaitre Vascular by 63.1% in the second quarter. Grandeur Peak Global Advisors LLC now owns 161,010 shares of the medical instruments supplier’s stock worth $15,451,000 after purchasing an additional 62,287 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 0.9%

LMAT stock opened at $81.52 on Friday. The company has a market capitalization of $1.86 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 2.35 and a beta of 0.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. LeMaitre Vascular has a one year low of $78.22 and a one year high of $118.01. The company’s 50 day moving average price is $85.61 and its two-hundred day moving average price is $97.13.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. During the same period last year, the company posted $0.60 EPS. LeMaitre Vascular’s revenue for the quarter was up 9.6% on a year-over-year basis. As a group, analysts predict that LeMaitre Vascular will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th were given a $0.25 dividend. The ex-dividend date was Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s payout ratio is presently 35.09%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures and markets medical devices used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on arteries and veins outside the heart and brain.

The company’s portfolio includes biologic and synthetic vascular grafts, thrombectomy catheters, angioplasty balloons, valvulotomes, vascular shunts, vessel-closure devices and other surgical instruments. LeMaitre also offers products used in vessel preparation, plaque removal and the repair or replacement of diseased blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular serves customers in the United States and international markets.